Plasmodium falciparum causes the most deadly form of malaria and accounts for over one million deaths annually. The malaria parasite is unable to salvage pyrimidines and relies on de novo biosynthesis for survival. Dihydroorotate dehydrogenase (DHOD), a mitochondrially localized flavoenzyme, catalyzes the rate-limiting step of this pathway and is therefore an attractive antimalarial chemotherapeutic target. Using a target-based high-throughput screen, we have identified a series of potent, species-specific inhibitors of P. falciparum DHOD (pfDHOD) that are also efficacious against three cultured strains (3D7, HB3, and Dd2) of P. falciparum. The primary antimalarial mechanism of action of these compounds was confirmed to be inhibition of pfDHOD through a secondary assay with transgenic malaria parasites and, the structural basis for enzyme inhibition was explored through in silico structure-based docking and site-directed mutagenesis. Compound-mediated cytotoxicity was not observed with human dermal fibroblasts or renal epithelial cells. These data validate pfDHOD as an antimalarial drug target and provide chemical scaffolds with which to begin medicinal chemistry efforts.
Plasmodium falciparum causes the most deadly form of malaria and accounts for over one million deaths annually. The malaria parasite is unable to salvage pyrimidines and relies on de novo biosynthesis for survival. Dihydroorotate dehydrogenase (DHOD), a mitochondrially localized flavoenzyme, catalyzes the rate-limiting step of this pathway and is therefore an attractive antimalarial chemotherapeutic target. Using a target-based high-throughput screen, we have identified a series of potent, species-specific inhibitors of P. falciparum DHOD (pfDHOD) that are also efficacious against three cultured strains (3D7, HB3, and Dd2) of P. falciparum. The primary antimalarial mechanism of action of these compounds was confirmed to be inhibition of pfDHOD through a secondary assay with transgenic malaria parasites and, the structural basis for enzyme inhibition was explored through in silico structure-based docking and site-directed mutagenesis. Compound-mediated cytotoxicity was not observed with human dermal fibroblasts or renal epithelial cells. These data validate pfDHOD as an antimalarial drug target and provide chemical scaffolds with which to begin medicinal chemistry efforts.
The current suite of approved antimalarial drugs is limited to only a few targets within the malignant human malaria parasite, Plasmodium falciparum, a sophisticated eukaryotic organism with approximately 5,300 genes. Widespread resistance to mainstay therapies such as chloroquine (CQ) (1) (2) (3) (4) , atovaquone (ATV) (5), pyrimethamine (PYR) (6) (7) (8) , and sulfadoxine (9) (10) (11) has created a need for new antimalarial agents. Herein, we address this issue through the identification and characterization of dihydroorotate dehydrogenase (DHOD) inhibitors with high specificity for the Plasmodium enzyme, submicromolar efficacy against cultured parasite strains, and no detectable cytotoxicity to human cells.
DHOD is a flavoenzyme that catalyzes the oxidation of L-dihydroorotate (L-DHO) to orotate as part of the fourth and rate-limiting step of the de novo pyrimidine biosynthetic pathway (Scheme 1) (12) (13) (14) (15) . The DHOD enzyme family can be separated by sequence homology into two broad classes that correlate with cellular localization and preference for electron acceptors (16) (17) (18) . Both classes of enzyme perform a two-step reaction that most likely proceeds through a ping-pong mechanism (19) (20) (21) (22) . Gram-positive bacteria and the budding yeast Saccharomyces cerevisiae use a Type 1 DHOD that is located in the cytosol and utilizes fumarate or NAD + as an electron acceptor to reoxidize the flavin (FMN) prosthetic group in the second half-reaction of the redox process (13, (23) (24) (25) (26) . Type 2 DHODs are membrane-bound and generally found in eukaryotes and some Gram-negative bacteria (27) (28) (29) (30) . This class of enzyme uses quinones located in biological membranes as an electron acceptor (31) . Specifically, eukaryotic Type 2 DHODs are localized to the inner mitochondrial space and utilize the respiratory chain quinone coenzyme Q n (CoQ n ), where the number of isoprenoid units (n) is variable, as a final electron acceptor (32) (33) (34) (35) . Humans and all characterized members of the genus Plasmodium utilize a Type 2 DHOD for de novo pyrimidine biosynthesis (34) (35) (36) (37) (38) .
Pyrimidines are required for the biosynthesis of DNA, RNA, glycoproteins, and phospholipids. Most organisms possess both a salvage and de novo pyrimidine biosynthetic pathway; however, the P. falciparum genome lacks necessary components in the pyrimidine salvage pathway rendering the parasite entirely dependent on de novo biosynthesis (39, 40) . Previous studies have shown that during the erythrocytic stages of P. falciparum development the mitochondrial electron transport chain exists solely to regenerate CoQ n to serve as an electron acceptor for DHOD (41) . Although the salvage pathway for pyrimidines is generally able to fulfill the majority of metabolic needs in human cells, rapidly dividing cells such as activated T-and Blymphocytes require de novo biosynthesis for sustained growth. The active metabolite of the Food and Drug Administration approved immunomodulatory drug leflunomide, A77 1726, is an inhibitor of human DHOD (hsDHOD) that exploits this specific vulnerability for the treatment of rheumatoid arthritis (42) (43) (44) (45) . A number of other DHOD inhibitors have been described for Helicobacter pylori and Escherichia coli that exhibit species-selectivity with respect to the human enzyme (46, 47) . Furthermore, speciesselectivity in designing small molecule inhibitors of P. falciparum DHOD (pfDHOD) should be possible as X-ray crystal structures of hsDHOD and pfDHOD in complex with A77 1726 and orotate show variability in both sequence and alignment of residues near the inhibitor binding site (48, 49) . As a consequence of this structural variability, A77 1726 is a potent inhibitor of the human enzyme but a very poor inhibitor of pfDHOD (50) . Combined, these findings indicate that small molecule inhibitors of pfDHOD could be useful chemotherapeutic agents for malaria.
While our primary goal was to identity inhibitors of pfDHOD that possessed activity against P. falciparum, we also tested inhibitors for activity against DHOD from the benign human malaria parasite Plasmodium vivax and the causative agent of rodent malaria, Plasmodium berghei. P. vivax malaria poses an enormous economic burden throughout many developing countries (51) , and it would be advantageous to develop a single drug with efficacy against both pfDHOD and P. vivax DHOD (pvDHOD). The rodent malaria enzyme was examined because the accepted drug development pathway for P. falciparum malaria uses a P. berghei mouse model. All three DHOD proteins share significant homology and thus, it was hypothesized that candidate pfDHOD inhibitors may be efficacious against DHOD enzymes from other Plasmodium spp.
Experimental Procedures
DHOD Plasmid Construction. PfDHOD was sub-cloned into the pET101D vector (Invitrogen, Carlsbad, CA) from a previously described codon-optimized, synthetic gene encoding amino acids 159-565 (49) . Site-directed mutant pfDHOD-pET22b expression constructs (H185A, F188A, F227A, R265A, I272A, Y528A, L531A) were kindly provided by M. Phillips from the University of Texas Southwestern Medical Center (50, 52, 53) . Both wild-type and mutant pfDHOD constructs were in-frame with a Cterminal 6xHis tag. Full-length, codon optimized DNA encoding the pbDHOD and pvDHOD genes were donated by GlaxoSmithKline (Philadelphia, PA) and sub-cloned into the pET101D expression vector in-frame with the C-terminal 6xHis tag. To improve solubility, the P. berghei and P. vivax DHOD genes were truncated to include amino acids 132-518 and 160-573, respectively, based upon sequence alignment with pfDHOD. HsDHOD was subcloned into the pET101D expression vector in an analogous manner to the Plasmodium DHOD orthologs from a previously described expression plasmid with the final construct encoding amino acids 30-396 (48) . Fulllength S. cerevisiae DHOD (scDHOD) was amplified from genomic DNA and cloned directly into the pET101D expression vector in-frame with the C-terminal 6xHis tag. The DHOD ORFs of all orthologs were sequenced in their entirety.
DHOD Expression and Purification. E. coli BL-21(DE3) cells (Invitrogen) transformed with either the wild-type or mutant pfDHOD, pvDHOD, pbDHOD, hsDHOD, or scDHOD expression constructs were grown in Terrific Broth with 100 µg/mL ampicillin at 30 °C. Protein expression was induced at OD 600 ~ 0.8 with the addition of isopropyl-beta-Dthiogalactopyranoside at a final concentration of 200 µM. The cultures were grown overnight at 22 °C. Cells were pelleted by centrifugation at 7,000×g at 4 °C and frozen at -20 °C for later use.
All subsequent purification steps were performed at 4 °C. Bacterial pellets were thawed in lysis buffer (50 mM HEPES (pH 7.5), 500 mM NaCl, 40 mM Imidazole, 0.1% Triton X-100) supplemented with Complete EDTA-free Protease Inhibitor Cocktail Tablets (Roche Applied Science, Indianapolis, IN). The cells were lysed by sonication and clarified by centrifugation at 48,000×g for 20 min. The supernatant was applied to a low-pressure column of Ni-NTA resin (Invitrogen) pre-equilibrated in Buffer A (50 mM HEPES (pH 7.5), 500 mM NaCl, 40 mM Imidazole, 0.1% Triton X-100, 5 mM 2-mercaptaethanol). The column was washed with Buffer A until the A 280 reached a stable baseline; bound DHOD was eluted with Buffer B (50 mM HEPES (pH 7.5), 500 mM NaCl, 400 mM Imidazole, 0.1% Triton X-100, 5 mM 2-mercaptaethanol). The eluted protein was serially dialyzed against Buffer C (50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 0.1% Triton X-100). Purity was assessed by SDS-PAGE and found to be greater than 85% for all DHOD enymes.
Total protein concentration was determined by Bradford analysis. DHOD requires a bound FMN cofactor for catalysis and thus, the concentration of FMN should equal the concentration of active protein (36, 54) . FMN concentration was measured spectrophotometrically at 445 nM (ε 445 = 12.5 mM -1 cm -1 ) by heat-denaturing the protein to release bound cofactor. Purified DHOD was aliquoted, flash-frozen in liquid N 2 , and stored at -80 o C for later use. High-throughput screen to identify pfDHOD inhibitors. The chromogen reduction assay was adapted for a high-throughput screen (HTS) for inhibitors of pfDHOD activity in 384-well plates based upon previous studies (53) . The assay was performed in a final volume of 50 µL of 100 mM HEPES (pH 8.0), 150 mM NaCl, 5% glycerol, 0.05% Triton X-100, 175 µM L-DHO, 11 µM decylubiquinone (CoQ D ), 95 µM 2,6-dichlorophenol-indophenol (DCIP), and 10 nM pfDHOD.
Compounds from the Genzyme Corporation (Cambridge, MA) Small Molecule Library, comprised of 208,000 diverse, largely commercially available molecules, were pintransferred into the 384-well assay plates to a final drug concentration of 10 µM for the initial screen. The reaction proceeded at room temperature for 20 min after which A 600 was measured using an automated microplate reader. The quality of data from the final assay was assessed using a statistical measure described by Zhang et al. (55) where the Z-factor ≈ 0.6; a Z-factor between 0.5 and 1 is generally favorable for an HTS. Primary hits were defined as compounds that inhibited ≥ 70% of pfDHOD activity at the initial screening concentration of 10 µM. These compounds were re-tested at a concentration of 1 µM and those that inhibited ≥ 50% of enzymatic activity were selected for half-maximal inhibitory concentration (IC 50 ) determination.
Re-screening of primary hits from pfDHOD screen and chemical analogs. Analogs of primary hits were purchased, as available, from ChemDiv (San Diego, CA) and Maybridge (Cornwall, UK). The purity of these compounds was greater than 90%. The active metabolite of leflunomide, A77 1726, was purchased from Axxora Life Sciences (San Diego, CA). IC 50 values, with respect to pfDHOD activity for candidate compounds, were calculated using the aforementioned 384-well based chromogen reduction assay with 16-24 different drug concentrations and reagent concentrations of 200 µM L-DHO, 18 µM CoQ D , 100 µM DCIP, and 10 nM pfDHOD. The concentration of CoQ D is approximately equivalent to the reported K m and the concentration of L-DHO is in excess (49, 50) . Select compounds were assayed in an analogous manner for the inhibition of site-directed pfDHOD mutants, pvDHOD, pbDHOD, or hsDHOD. The reported K m of CoQ D for pbDHOD, pvDHOD, hsDHOD, and pfDHOD variants with point mutations at H185A, F188A, F227A, R265A, I272A, or Y528A, L531A is approximately equivalent to that of wild-type pfDHOD and thus, the substrate concentrations used to assay enzyme activity and calculate IC 50 values was kept constant between the various proteins that were examined (37, 52, 56, 57) . Inhibition of scDHOD, a Type 1 DHOD, was evaluated using the DCIP assay described above for Type 2 DHOD enzymes except that 115 µM fumarate was used in lieu of CoQ D . The concentration of fumarate corresponds with the reported substrate K m while the concentration of L-DHO is in excess (58) . DHOD activity using FeCy as an electron acceptor was measured continuously in a UVtransparent cuvette. The assay was performed in a final volume of 100 µL of 100 mM HEPES (pH 8.0), 150 mM NaCl, 5% glycerol, 0.05% Triton X-100, 200 µM L-DHO, 100 µM ferricyanide (FeCy). Both the reduction of FeCy and the formation of orotate was monitored at 420 nm (ε 420 = 1 mM -1 cm -1 ) and 290 nm (ε 280 = 2 mM -1 cm -1 ), respectively, noting that two molecules of FeCy are reduced for one molecule of L-DHO. As with the previous assay, the reaction was performed at 25 o C and initiated with the addition of 5-10 nM of enzyme.
Inhibition ○ C and 5% CO 2 . Cell viability was assessed after 96 hrs by staining with Alamar Blue (Biosource International, Camarillo, CA). Cytotoxicity to renal proximal tubule epithelial cells was evaluated using the same method as described above except that the Renal Epithelial Growth Medium Bullet Kit (Clonetics, San Diego, CA) was used in lieu of EMEM and the renal epithelial cells were diluted to 1.5×10 4 cells/mL prior to aliquoting into 96-well plates.
Results
High-throughput screen to identify inhibitors of pfDHOD. DHOD catalyzes the oxidation of L-DHO to orotate via a ping-pong mechanism using a FMN cofactor that is reoxidized by the second substrate, CoQ n (Scheme 1). Enzymatic activity of DHOD can be assessed in the presence of L-DHO and CoQ n by directly measuring the formation of orotate or coupling the assay to the chromogen DCIP.
The latter colorimetric assay was adapted for an HTS of recombinant pfDHOD in 384-well plates in a manner similar to that described by Baldwin et al. (53) . CoQ D was chosen as the second substrate as it is significantly more soluble than ubiquinone (CoQ 10 ) and has been previously described to be efficiently utilized by pfDHOD (50, 63) . The concentration CoQ D used in the HTS was approximately equivalent to the reported K m for both hsDHOD and pfDHOD, and the concentration of L-DHO was in slight excess (49, 50) . The optimized screening assay afforded a Z-factor ≈ 0.6, a value between 0.5 and 1 is generally considered favorable for an HTS (55) .
The Genzyme Corporation chemical library of 208,000 compounds was screened for inhibitors of pfDHOD at an initial drug concentration of 10 µM; 689 (0.3%) compounds were found to inhibit ≥ 70% of pfDHOD activity when compared to control reactions containing no drug. These compounds were cherry-picked and re-tested at concentration of 1 µM yielding 55 compounds that inhibited ≥ 50% of pfDHOD activity. Dose-effect curves identified 38 (0.02%) compounds with submicromolar IC 50 values with respect to pfDHOD activity.
The long, hydrophobic quinone binding tunnel of pfDHOD likely accommodates a variety of ligands, which is consistent with the core structural diversity of compounds identified that inhibit the enzyme (49) . While many different core structures were represented among the most potent inhibitors, a larger than expected number of amide moieties conjugated to large aromatic rings were classified as hits from the HTS. This same bias was also observed by Baldwin et al. (53) in a comparable HTS for pfDHOD inhibitors.
Inhibition of cultured P. falciparum parasites by DHOD inhibitors. From the 38 pfDHOD inhibitors that were evaluated for antimalarial efficacy using P. falciparum 3D7 as the test strain, five compounds were found to have submicromolar IC 50 values (Table 1) . These compounds were then tested for inhibitory activity against multidrug-resistant HB3 and Dd2 P. falciparum strains. The 3D7 strain is sensitive to common antimalarials such as CQ and PYR and thus, is ideal for preliminary evaluation of candidate drugs. The HB3 and Dd2 strains are derived from patient isolates and are resistant to CQ and/or PYR (HB3: CQ sensitive, PYR resistant; Dd2: CQ resistant, PYR resistant) (64, 65) . Antimalarial efficacy of the pfDHOD inhibitors was consistent between the three different strains of P. falciparum. Compoundmediated cytotoxicity towards human dermal fibroblasts or renal epithelial cells was not observed at concentrations up to 60 µM.
Inhibitory activity and species-selectivity of screening hits against DHOD orthologs. All five pfDHOD inhibitors were found to possess antimalarial activity greater than 20-fold selective for pfDHOD over hsDHOD (Table 1) . Compounds 2-5 were also equally efficacious against pbDHOD and pvDHOD, enzymes which are highly homologous to pfDHOD (72% and 65% identity, respectively).
Mode of pfDHOD inhibition. Calculation of meaningful inhibition constants by steady-state kinetic analysis is difficult when examining twosubstrate enzymatic reactions and is further complicated when studying a ping-pong mechanism such as that catalyzed by DHOD. Malmquist et al. (52) demonstrated that the K m app for CoQ n to pfDHOD likely reflects multiple kinetic steps and thus, does not necessarily represent a traditional K m . In the absence of CoQ n , the nonspecific inorganic oxidants FeCy or O 2 can reoxidize the FMN cofactor presumably via a direct electron-transfer pathway (52) . Therefore, we evaluated 1-5 for inhibition of pfDHOD activity using FeCy as the terminal electron acceptor. None of the compounds significantly inhibited this reaction at a concentration of 50 µM whereas pfDHOD activity was fully inhibited using the endogenous substrate with an equal inhibitor concentration (data not shown). Inhibition of hsDHOD activity by A77 1726 with FeCy as the final electron acceptor was minimal in contrast to complete inhibition of catalysis afforded when using CoQ n as the second substrate. Ineffective inhibition of DHOD activity when using FeCy as an artificial substrate suggests a mechanism of inhibition that is specific to the transfer of electrons from FMN to CoQ n reminiscent of an inhibitor situated in the long, hydrophobic tunnel.
Mapping of the protein-ligand binding site. Although A77 1726 is a fairly weak inhibitor of pfDHOD activity, the protein-ligand binding pocket has been structurally defined by X-ray crystallography (48, 49, 66) .
Based upon this structural analysis and reports of other DHOD orthologs, it was hypothesized that 1-5 may lie in the same binding pocket as A77 1726 (67, 68) . Enzymatic inhibition of site-directed pfDHOD mutants were compared to wild-type protein using the chromogen reduction assay.
As previously reported, mutation of H185, F227, R265, I272, or Y528 to Ala reduced the affinity of A77 1726 for pfDHOD (Table 2) (37, 52, 56, 57) . Introduction of a point mutation at F188A did not significantly alter the affinity of A77 1726 or 1-5 for pfDHOD. A clear pattern between the various pfDHOD mutants and compound potency was not apparent (Table 2) . Nevertheless, the potency of 1, 3, 4, and 5 could be modulated through introduction of point mutations within the A77 1726 binding pocket; these data suggest an overlapping binding site albeit with altered ligand conformations.
Interestingly, the potency of 2 was not appreciably perturbed by mutating residues within the A77 1726 binding site. The CoQ n binding site was previously thought to overlap with that of A77 1726 (48, 49, 66) ; however, Malmquist et al. (52) have shown that the two binding sites are different. CoQ n and 2 share significant structural homology and thus, 2 may occupy the still undefined but distinct CoQ n binding site.
In silico docking of pfDHOD ligands. As a test case, a series of indole derivatives of 3 were purchased from commercial vendors. These were tested for inhibitory activity against purified pfDHOD protein and antimalarial efficacy ( Table  3) . Analysis of these compounds found that the bicyclic structure was necessary for activity: indoles and benzimidazoles performed well while piperidine and morpholine rings fared poorly. Docking simulations provided a structural basis for these findings. The multi-ring substituents were better able to fill a hydrophobic pocket in the proposed binding site (Figure 1) and, in particular, 3 formed hydrogen bonds to two critical pfDHOD residues (Supplemental Figure 1) .
Antimalarial mechanism of action. Although 1-5 are submicromolar inhibitors of pfDHOD enzymatic activity, their inhibitory action against the whole parasite could, in principle, involve pathways other than pfDHOD. A transgenic P. falciparum strain expressing a cytoplasmic Type 1 DHOD from S. cerevisiae, in addition to its endogenous mitochondrial pfDHOD, was generated to rule out this possibility. Painter et al. (41) had previously shown in an analogous experiment that the role of the mitochondrial electron potential, maintained in part by the cytochrome bc 1 complex, in the asexual stage of P. falciparum growth was mainly to reoxidize CoQ n to sustain pfDHOD activity and subsequent de novo pyrimidine biosynthesis (41, 69) . Consistent with this observation, the dose-effect curve for the D10-scDHOD parasite strain grown in the presence of ATV, an inhibitor of the cytochrome bc 1 complex, demonstrated significantly reduced drug efficacy when compared to the D10 parent strain (Supplemental Figure 2) . Complete resistance to ATV was not observed, an effect likely caused by variations in the copy number of the scDHOD expression plasmid among the transgenic parasite population. Nevertheless, the D10-scDHOD parasite strain was effectively engineered to largely bypass the pfDHOD pathway. The antimalarial activity of CQ is attributed to the inhibition of heme polymerization within the parasite and thus, both the D10 and D10-scDHOD P. falciparum strains were found to be equally sensitive to this drug (70) (71) (72) (73) .
No inhibition of scDHOD enzymatic activity was observed in the presence of 1-5 at 30 µM.
Dose-effect curves measuring parasite proliferation for both the parent and D10-scDHOD strains grown in the presence of 1-5 are shown in Supplemental Figure 2 . The antimalarial efficacy of 2-5 against the D10-scDHOD strain is significantly reduced when compared to the parent parasite strain. Specifically, growth inhibition of the transgenic parasite strain by these four compounds affords a biphasic drug-effect profile where the IC 50 values for the second phase of curve is greater than 10 µM (Table 4) . This rescued death phenotype concomitant with the addition of exogenous scDHOD argues that pfDHOD is the likely, and primary, in vivo target of 2-5. Although the dose-effect profile of 1 with regard to the scDHOD expressing parasites was shifted in comparison to the parent strain, significant inhibition of the transgenic parasite proliferation ensued at drug concentrations above 5 µM. The antimalarial activity of 1 may therefore involve multiple targets in addition to pfDHOD.
Discussion
The continued development of novel antimalarial chemotherapies, particularly those aimed at new pathways, is necessary for the successful treatment of malaria as resistance to presently utilized drugs becomes more widespread. To address this need, we have focused our drug discovery efforts on pfDHOD, the rate-limiting enzyme in the de novo pyrimidine biosynthetic pathway. Unlike its human host, the malaria parasite does not possess a salvage pathway for pyrimidines and must rely on de novo biosynthesis for its metabolic needs. PfDHOD is therefore likely to be an essential enzyme and homologs from other species have previously been shown to be amenable to small molecule inhibition.
A library of 208,000 compounds was screened for enzyme inhibitors of pfDHOD. A total of 38 compounds were identified as submicromolar inhibitors of which 33 were specific for pfDHOD as compared to hsDHOD. The low observed hit rate of 0.018% is a consequence of the stringent screening criteria. Baldwin et al. (53) performed an analogous HTS in which a relatively high proportion of hits contained amide and urea moieties conjugated to large aromatics. We too observed a similar selection of amide moieties conjugated to large aromatic rings but did not identify any of the same molecules indicating that the two different chemical libraries likely have few compounds and scaffolds in common.
Potent, species-selective inhibitors of pfDHOD have been previously described, but in vitro antimalarial efficacy has thus far been elusive. Here, we identified five inhibitors of pfDHOD that also possess submicromolar antimalarial activity.
To the best of our knowledge, this is first report of an HTS for pfDHOD inhibitors that has yielded candidate drugs that are both specific for the Plasmodium enzyme and efficacious in the whole parasite assay. No adverse cytotoxicity attributed to these compounds was apparent in kidney epithelial cells or dermal fibroblasts. A transgenic P. falciparum strain expressing a Type 1 DHOD from S. cerevisiae confirmed inhibition of pfDHOD to be the primary mechanism of action for 2-5. Numerous antimalarial drugs based upon a 4-aminoquinoline core scaffold have been shown to inhibit heme polymerization and thus, it is not surprising that 1 may inhibit parasite proliferation via mechanisms in addition to the inhibition of pfDHOD (74) .
Inhibition profiles of wild-type versus mutant pfDHOD was used to localize the binding site of 1, 3, 4, and 5 to be on or about that of A77 1726. Compound 2, however, is believed to bind a distinct site, likely that of the CoQ substrate based upon structural similarities.
Our findings confirm the value of pfDHOD as a target for antimalarial chemotherapy. The advancement of any of the candidate compounds presented here along a drug development path will require a significant investment in medicinal chemistry. Nevertheless, these chemical scaffolds provide a starting point for further development.
Indeed, in silico modeling and structure-activity exploration of 3 and a series of structural analogs have afforded insight with regards to hit optimization. 50 values were determined using a continuous assay where the reagent concentrations were 200 µM L-DHO, 18 µM CoQ D , 100 µM DCIP, and 10 nM DHOD. Data obtained using mutant pfDHOD proteins were normalized to wild-type enzyme and represent at least three determinations using 16 different drug concentrations. Table 3 . Structure-activity relationship of 3. A) The parent compound, 3, forms a hydrogen bond between a carbonyl and Y528 and another bond between the amide hydrogen and G181.
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B) The related but ineffective analog 8 forms only a single hydrogen bond between its carbonyl moiety and H185 which may, in part, be responsible for its diminished inhibitory efficacy.
